Product Information
ROPINIROLE HCL ER 8 MG TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $0.9066 per EA under NDC 00228366009. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on May 17, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
8 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00228366009
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ROPINIROLE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090869FDA Approved
5/17/2012
TE Code
AB
On Market Since
8/23/2012
Pharmacological Classes
Price Statistics
The NADAC for ROPINIROLE HCL ER 8 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 82.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9066 per EA |
|---|---|
| All-time high | $5.9283 (Feb 12, 2014) |
| All-time low | $0.7082 (Nov 23, 2022) |
| 52-week high | $1.3896 |
| 52-week low | $0.7180 |
| Median price | $2.1352 |
| Average price | $2.5363 |
| Largest weekly change | +104.0% (Dec 21, 2022) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ropinirole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonergot Dopamine Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ROPINIROLE HCL ER 8 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROPINIROLE HCL ER 8 MG TABLET, manufactured by Actavis Pharma, Inc., is $0.9066 per EA (NDC 00228366009), effective Sep 30, 2026.
How has the price of ROPINIROLE HCL ER 8 MG TABLET changed over time?
Over the history we have for it, the NADAC for ROPINIROLE HCL ER 8 MG TABLET has declined 82.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ROPINIROLE HCL ER 8 MG TABLET?
Since Nov 28, 2013, the NADAC for ROPINIROLE HCL ER 8 MG TABLET has ranged from a low of $0.7082 (Nov 23, 2022) to a high of $5.9283 (Feb 12, 2014), with a median of $2.1352 per EA.
Are there cheaper alternatives to ROPINIROLE HCL ER 8 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ROPINIROLE HCL ER 8 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ROPINIROLE HCL ER 8 MG TABLET?
ROPINIROLE HCL ER 8 MG TABLET (NDC 00228366009) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.